Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to
Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.